


中国药学会系列期刊/《CAJ-CD》规范执行优秀期刊/美国《化学文摘》荷兰SCOPUS等国际著名检索系统收录  
中国中文核心期刊 中国科技核心期刊 中国科学引文数据库来源期刊

CHINESE JOURNAL OF NEW DRUGS

ISSN 1003-3734  
CN 11-2850/R  
CODEN ZXZHA6

# 中国新药杂志



7  
2015  
Vol.24 | No.7

探讨药物国际多中心临床试验设计的一种新方法SGDDP

我国化学仿制药生产企业申请达到WHO药品预认证标准的激励因素和  
技术差距研究

我国医药产业区域布局结构趋同性及影响因素研究

丹酚酸B的药动学及相关研究进展

甘草酸二铵对雷公藤甲素诱导肠通透增强及染色体损伤的保护作用

www.newdrug.cn

ISSN 1003-3734



国家食品药品监督管理局主管



•新药述评与论坛•

- 721 探讨药物国际多中心临床试验设计的一种新方法SGDDP.....黄钦, 王骏, 曲荣华, 等  
725 我国化学仿制药生产企业申请达到WHO药品预认证标准的激励因素和技术差距研究...黄宝斌, Christina Forge-Wimmer, 孙新生, 等  
730 我国医药产业区域布局结构趋同性及影响因素研究.....徐怀伏, 王欣  
737 基于药品研发周期构建多向风险管理机制.....李章明, 朱文良, 刘兰茹, 等  
741 基于定价和补偿角度探讨罕用药价格规制体系.....常峰, 商晓婷

•新药申报与审评技术•

- 745 试谈中药提取工艺中使用大孔吸附树脂纯化的研究要求与评价.....宋丹, 张永文

•重大新药创制专项巡礼•

- 750 甘草酸二铵对雷公藤甲素诱导肠通透增强及染色体损伤的保护作用.....淡墨, 文海若, 闻隰, 等  
755 阿戈美拉汀微粒型口崩片的质量研究.....周萧云, 张慧, 李志平, 等

•生物医药前沿•

- 760 离子交换层析法制备高纯度人凝血因子VIII的研究.....刘晓, 韩国德, 李青, 等

•综述•

- 765 新型化疗止吐药神经激肽-1受体拮抗剂的研究进展.....孙秀波, 何祎晨, 刘蕾  
771 PPAR $\gamma$ 激动剂的研究进展.....张瑜, 邢志佳, 马宇衡, 等  
778 微球在关节腔注射给药系统中的研究进展.....王丽娟, 车珂科  
782 含有缩酮(醛)的pH敏感聚合物作为药物载体的研究进展.....王杨, 顾准, 王伟, 等  
791 丹酚酸B的药理学及相关研究进展.....袁春平, 侯惠民, 区淑蕴  
800 温度敏感型凝胶基质的研究进展.....沈晶晶, 刘宏, 熊康萍

•临床研究•

- 804 盐酸戊乙奎醚片单次给药人体耐受性研究.....雍小兰, 李楠, 杜晓琳, 等  
808 他汀类药物治疗外周动脉粥样硬化的疗效比较.....谢坚, 王玉凯, 邵燕, 等

•实验研究•

- 813 蛹虫草中N<sup>6</sup>-(2-羟乙基)腺苷的提取分离及对小鼠睡眠的影响.....陈玉皎, 孙嘉辰, 张晓倩, 等  
818 聚缩酮PCADK的合成及胰岛素微球的制备与表征.....张峰涛, 马鹏凯, 王正, 等  
823  $\beta$ -细辛醚对抑郁模型大鼠昼夜节律周期基因*Per1*表达的影响.....董海影, 张春, 王俊革, 等  
827 盐酸可乐定缓释微丸制备工艺的探究.....李见春, 张红敏, 孙宏张, 等  
831 不同树脂对麻黄附子细辛汤中5种生物碱的洗脱性能比较.....曹洪杰, 杨彬彬, 容蓉, 等  
837 水杨酸甲酯立方液晶的研制.....吴晓晴, 桂双英, 陈玉林, 等

- 721 **Statistical considerations on a new design method for multiregional clinical trial: SGDDP**  
HUANG Qin, WANG Jun, QU Rong-hua, *et al*
- 725 **The incentives and technical gaps faced by Chinese manufacturers producing chemical generic medicines to achieve the standards of WHO Medicines Prequalification**  
HUANG Bao-bin, Christina Forge-Wimmer, SUN Xin-sheng, *et al*
- 730 **Structural convergence and influencing factors of Chinese pharmaceutical industry regional layout**  
XU Huai-fu, WANG Xin
- 737 **Constructing pharmaceutical R&D cycle-based multi-directional risk management mechanism**  
LI Zhang-ming, ZHU Wen-liang, LIU Lan-ru, *et al*
- 741 **Discussion about the orphan drug pricing regulation system from the perspective of pricing and reimbursement**  
CHANG Feng, SHANG Xiao-ting
- 745 **Requirement and evaluation of studies on using macroporus adsorption resin for further purification of extracts from Chinese herbal medicines**  
SONG Dan, ZHANG Yong-wen
- 750 **Protective effects of diammonium glycyrrhizinate on permeability increasing and chromosome breakage induced by *tripotide***  
DAN Mo, WEN Hai-ruo, WEN Nie, *et al*
- 755 **Quality evaluation of agomelation orally disintegrating tablets with multi-particulate form**  
ZHOU Xiao-yun, ZHANG Hui, LI Zhi-ping, *et al*
- 760 **Preparation of high purity human coagulation factor VIII using ion exchange chromatography**  
LIU Xiao, HAN Guo-de, LI Qing, *et al*
- 765 **Progress in research of neurokinin-1 receptor antagonists, new drugs for preventing and treating chemotherapy-induced nausea and vomiting**  
SUN Xiu-bo, HE Yi-chen, LIU Lei
- 771 **Research progress of PPAR $\gamma$  agonists**  
ZHANG Yu, XING Zhi-jia, MA Yu-heng, *et al*
- 778 **Progress of microspheres as intra-articular injection drug delivery system**  
WANG Li-juan, CHE Ke-ke
- 782 **Progress in researches for pH-sensitive polymer with ketal (acetal) bonds used as drug carriers**  
WANG Yang, GU Zhun, WANG Wei, *et al*
- 791 **Progress in the pharmacokinetics and relative studies of salvianolic acid B**  
YUAN Chun-ping, HOU Hui-min, OU Shu-yun
- 800 **Progress in research of temperature-sensitive gel matrix**  
SHEN Jing-jing, LIU Hong, XIONG Kang-ping
- 804 **Study on safety and tolerability of single-dose of penehyclidine hydrochloride in healthy volunteers**  
YONG Xiao-lan, LI Nan, DU Xiao-lin, *et al*
- 808 **Comparison of efficacy of two statins for peripheral artery atherosclerosis**  
XIE Jian, WANG Yu-kai, SHAO Yan, *et al*
- 813 **Effects of N<sup>6</sup>-(2-hydroxyethyl)adenosine in *Cordyceps militaris* on the hypnotic of mice**  
CHEN Yu-jiao, SUN Jia-chen, ZHANG Xiao-qian, *et al*
- 818 **Synthesis of polyketal-PCADK and preparation and characterization of insulin microspheres**  
ZHANG Feng-pu, MA Peng-kai, WANG Zheng, *et al*
- 823 **Effect of  $\beta$ -asarone on expression of circadian genes *Per1* in rat model of depression**  
DONG Hai-ying, ZHANG Chun, WANG Jun-ping, *et al*
- 827 **Investigation of the preparation technique of clonidine hydrochloride sustained-release pellets**  
LI Jian-chun, ZHANG Hong-min, SUN Hong-zhang, *et al*
- 831 **Comparison of the elution properties of different resins for five alkaloids in Mahuang-fuzi-xixin decoction**  
CAO Hong-jie, YANG Bin-bin, RONG Rong, *et al*
- 837 **Preparation of cubic liquid crystal as a drug delivery system for methylsalicylate**  
WU Xiao-qing, GUI Shuang-ying, CHEN Yu-lin, *et al*

**Directed by:** China Food and Drug Administration

**Sponsored by:** China Medical Science Press

China National Pharmaceutical Group Corp.  
Chinese Pharmaceutical Association

**Editor-in-Chief:** SANG Guo-wei

**Board Chairman:** SHI Sheng-yi

**Edited by:** Editorial Board of Chinese Journal of New Drugs

**Published by:** Chinese Journal of New Drugs Co., Ltd.

**Address:** Room 1605, No.2 Ocean Cityscape, No.123 Zhongguancundonglu,  
Haidian District, Beijing 100086, China

**Tel:** (010)80442198 / 82282300 / 80442188 / 80442189 / 82282326

**Fax:** (010)82282289

**Website:** <http://www.newdrug.cn>

**E-mail:** [bianjibu@newdrug.cn](mailto:bianjibu@newdrug.cn)

**Printer:** Beijing Kexin Printing Co., Ltd.

**Domestic Distribution:** Beijing Post Offices

**Overseas Distribution:** China International Book Trading Corp.  
(P.O.Box 399 Beijing, China)

**Domestic Subscription:** Local Post Offices

**Periodical Registration:** ISSN 1003-3734 CN 11-2850/R

**Publication Date:** April 15, 2015




**Copyright:** 2015 by Chinese Journal of New Drugs Co., Ltd.

 泰勒宁<sup>®</sup>  
氨酚羟考酮片

# 口服复方制剂

## 适用于各种中重度急慢性疼痛



-  双重机理，协同作用，中重度镇痛
-  复方制剂，口服给药
-  普通处方管理

### 【简要处方】

【成份】本品为复方制剂。

其组分为：每片含盐酸羟考酮5mg，对乙酰氨基酚325mg。

【适应症】适用于各种中、重度急慢性疼痛。

【用法用量】成人常规剂量为每6小时服用1片，可根据疼痛程度和给药后反应来调整剂量。对于重度疼痛的患者或对阿片类镇痛药产生耐受性的患者，必要时可超过推荐剂量给药。

【不良反应】最常见的非严重的不良反应包括：头昏、眩晕、嗜睡、恶心、呕吐。运动时加重，休息时减轻。偶见精神亢奋、烦躁不安、便秘和皮肤瘙痒。

【批准文号】国药准字J20100119

【进口药品注册证号】H20100367

【进口生产企业】MALLINCKRODT INC. USA

【国内分包装企业】国药集团工业有限公司

请遵医嘱处方购买和使用，详细处方资料请参阅产品说明书。

本广告仅供医学药学专业人士阅读。 京药广审(文)第2014050375号



国药控股北京华鸿有限公司

地址：北京市东城区光明路11号天玉大厦508室 邮编：100061

电话：010-51902299

传真：010-51902111

国内定价：30.00元

国内统一刊号CN11-2850/R

邮发代号82-488

国外代号M4240